High-dose rituximab and anti-MAG-associated polyneuropathy

Neurology. 2006 Mar 14;66(5):742-4. doi: 10.1212/01.wnl.0000201193.00382.b3.

Abstract

Rituximab has been administered successfully in patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750 mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody-Dependent Cell Cytotoxicity
  • B-Lymphocytes / immunology
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin M / blood
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Myelin-Associated Glycoprotein / immunology*
  • Polyneuropathies / drug therapy*
  • Polyneuropathies / immunology*
  • Rituximab
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunoglobulin M
  • Immunologic Factors
  • Myelin-Associated Glycoprotein
  • Rituximab